



## **Fierce Biotech: Tenaya tackles genetic heart condition after thorough screening process nails down target**

July 11, 2022

Writing for Fierce Biotech, reporter Max Bayer summarizes Tenaya's preclinical study for dilated cardiomyopathy published in July 2022. The study identified the HDAC6 inhibitor as a target for the potential treatment of DCM.

[Read More](#)